Search the Newsreel

Is Great West Lifeco (TSX:GWO) Fully Priced After Higher Earnings And A Bigger Buyback?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Great-West Lifeco (TSX:GWO) is back in focus after reporting higher net income and earnings per share for the second quarter and first half …

Great-West Lifeco Inc. Revenue Breakdown – TSX:GWO

Why PERFECT CORP (PERF) Might be Well Poised for a Surge

Top 3 Tech Stocks That Are Ticking Portfolio Bombs

The article identifies three technology stocks—InterDigital Inc (IDCC), AstroNova Inc (ALOT), and Perfect Corp (PERF)—that show signs of being overbought, according to their Relative Strength Index (RSI) values. These stocks have experienced significant recent gains, with IDCC rising 17% in five days, ALOT up …

Great-West Lifeco Inc. 2026 Q2 - Results - Earnings Call Presentation (TSX:GWO:CA) 2026-07-31

Key Points Interested in Great-West Lifeco Inc.? Here are five stocks we like better. Great-West Lifeco's Q2 base EPS rose 15% year over year, with base ROE at 19.3%, near its 19.5% medium-term target. Retirement and wealth client assets increased 22% to more than …

Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lifecore Biomedical Inc (LFCR), focusing on its price momentum, support and resistance levels, and various technical indicators, including moving averages. The current price momentum score is 4.32, with the stock trading between a resistance level of 5.16 …

Great-West Lifeco Inc (GWLIF) (Q2 2026) Earnings Call Highlights: Strong EPS Growth and Record ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Great-West Lifeco Inc (GWLIF) delivered 15% base EPS growth year-over-year, driven by double-digit growth at …

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical, Inc. announced that it will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. The company's senior management team will host a webcast at 8:00 a.m. Eastern Time on the …

Great-West Earnings: Solid Quarter, Acquisition of Milliman to Close in Second Half of 2026

Lifecore Sets Aug. 5 Webcast for Second-Quarter Results

Lifecore Biomedical (NASDAQ: LFCR) announced it will report its second-quarter financial results for the period ended June 30, 2026, on Wednesday, August 5, 2026, before market open. Senior management will host a webcast at 8:00 a.m. Eastern Time to discuss the results, with an …

BlackRock (LFCR holder) reports 2,010,546 Lifecore Biomedical shares in new ownership filing

BlackRock, Inc. has filed a Schedule 13G indicating a passive ownership stake in Lifecore Biomedical, Inc. (LFCR). BlackRock and its business units beneficially own 2,010,546 shares, representing 5.4% of Lifecore's common stock, with sole voting power over 1,988,535 shares and sole dispositive power over …

Great West President & Chief Executive Officer David Harney to join Virtual Fireside Chat with Jefferies

TSX:GWO WINNIPEG, MB, July 29, 2026 /CNW/ -- Great-West Lifeco Inc. (TSX: GWO) ("Great West") today announced that David Harney, President and Chief Executive Officer, Great West, will join Jefferies analyst John Aiken in a virtual fireside chat on Thursday, July 30, 2026, at …

Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Lifecore Biomedical Inc (LFCR), a company within the Pharmaceuticals industry. It highlights that LFCR has a risk assessment score of 4.90, ranking 78 out of 155 in its industry, and a beta value of 1.07. The report …

Lifecore Biomedical Inc (LFCR) Financial Health: Profitability & Balance Sheet Analysis

Lifecore Biomedical Inc (LFCR) currently holds a weak financial score of 6.79 out of 10, ranking 134th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 6.12% and a net profit decrease of 1.82% in …

Perfect Presentation for Commercial Services Co. Revenue Breakdown – TADAWUL:7204

Great West reports Q2 2026 results with double-digit earnings growth

TSX:GWO Great-West Lifeco Inc.'s Quarterly Report to Shareholders for the second quarter of 2026, including its Management's Discussion and Analysis (MD&A) and consolidated interim financial statements for the three and six months ended June 30, 2026, are available at greatwestlifeco.com/financial-reports and sedarplus.ca. Readers are …

Perfect Corp. Class A Revenue Breakdown – SWB:SZ9

This page provides financial overview for Perfect Corp. Class A (SWB:SZ9) on the Stuttgart Stock Exchange. It focuses on the company's financials, including revenue breakdowns by source and country, and offers various tools and community features for investors.

Lifecore Biomedical signs three new customer deals, boosting 2028 revenue outlook.

Lifecore Biomedical has secured three new customer agreements for early- and late-stage development programs, including a regenerative medicine project and a medical device formulation. These deals are expected to significantly contribute to the company's revenue growth by 2028. The agreements underscore Lifecore's broad technical …

Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline

Lifecore Biomedical (NASDAQ: LFCR) has announced three new customer agreements that will expand its pipeline in regenerative medicine and advanced medical technologies. These agreements include a late-stage regenerative medicine program and two early-stage programs focusing on formulation optimization, which are expected to contribute to …

Perfect Corp (NYSE: PERF) grows H1 profit and signs going-private deal

Perfect Corp. reported unaudited Q2 2026 results with stable total revenue of $16.3 million, but improved gross profit to $13.2 million and net income of $1.3 million due to higher margins and cost control. For the first half of 2026, revenue increased by 5.9% …

Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Lifecore Biomedical Inc (LFCR), listing its major individual shareholders and the proportion of shares they hold. It also breaks down shareholder types, such as hedge funds and investment advisors, and provides institutional shareholding data over several quarters, …

Perfect (PERF) Stock Faces Margin Hit As One Off Loss Tests Bullish Narratives

Perfect (PERF) reported mixed Q2 2026 results with US$16.3 million revenue, US$0.013 basic EPS, and US$1.3 million net income, leading to investor reassessment of its growth and profitability. A notable US$1.9 million one-off loss and a drop in net margin from 9.5% to 8.1% …

Perfect Corp. Reports Unaudited Financial Results for the Three Months and Six Months Ended June 30, 2026

Perfect Corp. (NYSE: PERF) announced its unaudited financial results for the three and six months ended June 30, 2026, showcasing significant improvements in net income and operating loss due to effective cost control and increased operational efficiency. The company reported stable total revenue for …

Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lifecore Biomedical Inc (LFCR)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past 5 years, indicating no recent dividend payouts. The page also presents current stock data for LFCR.

Perfect Corp Q2 EPS hits $0.01, sales miss estimates

Perfect Corp shares edge up on in-line earnings despite revenue miss

Perfect Corp. Delivers Higher Net Income on Stronger Gross Margins

Perfect Corp. (PERF) Lags Q2 Earnings and Revenue Estimates

Perfect Corp shares gain after earnings meet expectations

Perfect Corp. Swings to $1.4M Operating Income in First Half

Perfect Corp. (NYSE: PERF) announced its unaudited financial results for the three and six months ended June 30, 2026. The company swung to a $1.4 million operating income for the first half of 2026, compared to a $1.6 million operating loss in the same …

Frontera Energy Corporation Revenue Breakdown – TSX:FEC

LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100

This article provides a detailed financial summary for Lifecore Biomedical Inc (LFCR), including its recent stock performance, key financial statements like income, balance sheet, and cash flow. It highlights the company's latest earnings report with FY2025 revenue of $75.52M and an EPS of -$0.54, …

Perfect Corp (PERF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR

Lifecore Biomedical, Inc. (NASDAQ: LFCR) generated $75.52 million USD in total revenue last year. Its top-performing segment, "Lifecore," contributed $128.87 million USD, an increase from $128.26 million USD in the prior year. The United States was the primary regional contributor, accounting for the same …

PERF|Perfect Corp|Price:1.920|Chg%:-0.010

Perfect Corp (PERF) is trading at $1.92, down 0.52%, with a market cap of $195.55M. Analysts currently rate the stock as "Hold" with a target price of $3.00, suggesting a 55.44% upside, despite the stock being considered overvalued with a P/E of 42.33. The …

Lifecore Biomedical Inc (LFCR) Institutional Confidence

Lifecore Biomedical Inc (LFCR) has an institutional shareholding score of 7.00, placing it 50th in the Pharmaceuticals industry. Institutional investors hold 81.48% of its shares, an increase of 8.09% quarter-over-quarter. The largest institutional holder is ETHSX, with other significant holders including Wynnefield Capital, Inc. …